Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value
Background The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently. Me...
Saved in:
Published in | Frontiers in immunology Vol. 13; p. 982812 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
20.09.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently.
Methods
TIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity.
Result
Different member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging.
Conclusion
As immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker. |
---|---|
AbstractList | Background
The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently.
Methods
TIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity.
Result
Different member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging.
Conclusion
As immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker. BackgroundThe clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and tumor microenvironment in thyroid cancer was explored. The role of FOXP2 in tumor invasion and recurrence was investigated consequently.MethodsTIMER and GEPIA were firstly employed to compare FOXPs expression in normal and cancer tissues from multiple human cancers. The results from database were confirmed by quantitative Real Time-PCR and Western blot in matched thyroid cancer and adjacent normal tissues, in addition to a panel of thyroid cancer cell lines and normal thyroid cell. GEPIA platform was employed to discover the possibility of FOXPs as prognostic indicator. TISIBD and UACLCAN were then employed to estimate the influence of FOXPs on lymph node metastasis and tumor staging. GEPIA analysis was initially employed to analyze correlation of FOXPs and tumor immune infiltrating cells, and TIMER dataset was then included for standardization according to tumor purity.ResultDifferent member of FOXPs showed divergence in expression in various cancer tissues. Lower FOXP1, FOXP2 and higher FOXP3, FOXP4 levels could be identified in thyroid cancer tissues when compared with matched normal tissue. There was an inverse correlation between FOXP2, FOXP4 and immune invasion, whereas FOXP1 and FOXP3 were positively correlated. FOXPs showed remarkable correlations with multiply immune cells. More importantly, only FOXP2 showed the significant effect on recurrence and tumor staging.ConclusionAs immune regulatory factor, the reduction of FOXP2 may affect tumor microenvironments and immune cells infiltration, enhance tumor immune escape, and promote recurrence of thyroid cancer. FOXP2 could be a new potential diagnostic and prognostic marker. |
Author | Xu, Lianghui Zhan, Lin Yan, Jiqi Zhao, Qiwu Yang, Zheyu Liu, Zhuoran Chen, Linxie Kuang, Jie Feng, Haoran Qiu, Weihua Cai, Wei |
AuthorAffiliation | Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China |
AuthorAffiliation_xml | – name: Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , China |
Author_xml | – sequence: 1 givenname: Lianghui surname: Xu fullname: Xu, Lianghui – sequence: 2 givenname: Zheyu surname: Yang fullname: Yang, Zheyu – sequence: 3 givenname: Qiwu surname: Zhao fullname: Zhao, Qiwu – sequence: 4 givenname: Haoran surname: Feng fullname: Feng, Haoran – sequence: 5 givenname: Jie surname: Kuang fullname: Kuang, Jie – sequence: 6 givenname: Zhuoran surname: Liu fullname: Liu, Zhuoran – sequence: 7 givenname: Linxie surname: Chen fullname: Chen, Linxie – sequence: 8 givenname: Lin surname: Zhan fullname: Zhan, Lin – sequence: 9 givenname: Jiqi surname: Yan fullname: Yan, Jiqi – sequence: 10 givenname: Wei surname: Cai fullname: Cai, Wei – sequence: 11 givenname: Weihua surname: Qiu fullname: Qiu, Weihua |
BookMark | eNpVkc1qHDEQhIfgQBzHD5CbjrnsZtSaH-kSCMZODAb74EBuokdq2TIz0kbSGPz20e6aEOuiorv0dYv62JyEGKhpPvN2K4RUX51flnULLcBWSZAc3jWnfBi6jQDoTv7TH5rznJ_aejolhOhPm3DpHJnComNXt7_vgJWEIZvkd8XHwByaEhOraj8iEPPB-bl6Dt36qDy-pOgtMxgMJYbBMl8y28VCoXicmZl98KaKZ5xX-tS8dzhnOn-9z5pfV5f3Fz83N7c_ri--32xM10HZTDgY7qQiQ5MYoUXVYi-RJsUVqLp6i6ITk-StAotTb7vBiB6mAWhU1oA4a66PXBvxSe-SXzC96IheHwoxPWhMxZuZNIdxlFZOxKnrektywt7A4NyojBycraxvR9ZunRaypn4s4fwG-rYT_KN-iM9a9YLDICvgyysgxT8r5aIXnw3NMwaKa9YwguC95IOoVn60mhRzTuT-jeGt3metD1nrfdb6mLX4C8MJokY |
CitedBy_id | crossref_primary_10_3390_cancers15051468 |
Cites_doi | 10.1080/23723556.2015.1019022 10.1093/intimm/dxac013 10.3389/fimmu.2021.613492 10.1172/JCI32538 10.1186/s40425-018-0378-y 10.1186/s12943-019-1110-3 10.1038/s41416-021-01340-x 10.1038/sj.leu.2403644 10.7759/cureus.4127 10.1007/s13277-015-3701-y 10.1016/j.pharmthera.2017.08.003 10.1038/nrg2523 10.3389/fendo.2020.570604 10.3390/ijms20184413 10.3390/vaccines4040041 10.1080/15384047.2018.1537999 10.1158/1078-0432.CCR-16-0484 10.1038/modpathol.2008.74 10.1186/s12885-019-5380-3 10.1136/jclinpath-2012-201335 10.1016/S2213-8587(21)00027-9 10.3892/etm.2022.11361 10.1210/jc.2011-3428 10.18632/aging.101918 10.3892/mmr.2014.2197 10.1242/dev.112672 10.1093/molbev/msq182 10.1111/cpr.12312 10.1210/jc.2009-2564 10.3390/ijms19103279. 10.1111/cen.13369 10.1089/thy.2018.0684 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu |
Copyright_xml | – notice: Copyright © 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu 2022 Xu, Yang, Zhao, Feng, Kuang, Liu, Chen, Zhan, Yan, Cai and Qiu |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fimmu.2022.982812 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1664-3224 |
EndPage | 982812 |
ExternalDocumentID | oai_doaj_org_article_12778d8be1e445de8ba5c26ff79c86fd 10_3389_fimmu_2022_982812 |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW KQ8 M48 M~E OK1 PGMZT RNS RPM 7X8 ITC 5PM |
ID | FETCH-LOGICAL-c442t-ba6c1f89eceb3720a90a58aeb919299330a343b81092dab5d46c352b62e79dc23 |
IEDL.DBID | RPM |
ISSN | 1664-3224 |
IngestDate | Fri Oct 04 13:14:31 EDT 2024 Tue Sep 17 21:30:33 EDT 2024 Fri Aug 16 21:27:43 EDT 2024 Thu Sep 26 16:11:52 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-ba6c1f89eceb3720a90a58aeb919299330a343b81092dab5d46c352b62e79dc23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors have contributed equally to this work Edited by: Baochi Ou, First Affiliated Hospital of Anhui Medical University, China Reviewed by: Leqi Zhou, Second Military Medical University, China; Luigi Cari, University of Perugia, Italy; Hang Zhou, Harbin Medical University, China This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531268/ |
PQID | 2723158163 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_12778d8be1e445de8ba5c26ff79c86fd pubmedcentral_primary_oai_pubmedcentral_nih_gov_9531268 proquest_miscellaneous_2723158163 crossref_primary_10_3389_fimmu_2022_982812 |
PublicationCentury | 2000 |
PublicationDate | 2022-09-20 |
PublicationDateYYYYMMDD | 2022-09-20 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-20 day: 20 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in immunology |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Miranda-Filho (B1) 2021; 9 Santos (B17) 2011; 28 French (B33) 2012; 97 Yan (B24) 2015; 36 Stumm (B29) 2013; 66 Yang (B16) 2022; 23 Bach (B18) 2018; 19 Streubel (B11) 2005; 19 Golson (B7) 2016; 143 Iyer (B5) 2018; 6 Xie (B30) 2020; 11 Li (B26) 2015; 20 Goatly (B10) 2008; 21 Cuiffo (B22) 2016; 3 Xue (B21) 2014; 10 Poggi (B23) 2016; 4 Raue (B3) 2016; 22 Liang (B14) 2021; 125 Mehnert (B4) 2019; 19 Cuiffo (B20) 2016; 3 Hannenhalli (B8) 2009; 10 Liu (B15) 2019; 11 Zuo (B25) 2007; 117 Ahn (B31) 2019; 29 Kim (B12) 2019; 18 Nagasaki (B35) 2022 Nixon (B13) 2017; 87 Li (B27) 2017; 50 Ferrari (B6) 2019; 20 Peng (B32) 2021; 12 Wang (B28) 2015; 8 Wang (B9) 2018; 181 Olson (B2) 2019; 11 Sheng (B19) 2019; 20 French (B34) 2010; 95 |
References_xml | – volume: 3 year: 2016 ident: B22 article-title: Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis publication-title: Mol Cell Oncol doi: 10.1080/23723556.2015.1019022 contributor: fullname: Cuiffo – start-page: dxac013 year: 2022 ident: B35 article-title: A variety of ‘exhausted’ T cells in the tumor microenvironment publication-title: Int Immunol doi: 10.1093/intimm/dxac013 contributor: fullname: Nagasaki – volume: 12 year: 2021 ident: B32 article-title: Metabolism of dendritic cells in tumor microenvironment: For immunotherapy publication-title: Front Immunol doi: 10.3389/fimmu.2021.613492 contributor: fullname: Peng – volume: 117 year: 2007 ident: B25 article-title: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2 publication-title: J Clin Invest doi: 10.1172/JCI32538 contributor: fullname: Zuo – volume: 6 start-page: 68 year: 2018 ident: B5 article-title: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0378-y contributor: fullname: Iyer – volume: 18 start-page: 180 year: 2019 ident: B12 article-title: Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression publication-title: Mol Cancer doi: 10.1186/s12943-019-1110-3 contributor: fullname: Kim – volume: 125 start-page: 390 year: 2021 ident: B14 article-title: The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis publication-title: Br J Cancer doi: 10.1038/s41416-021-01340-x contributor: fullname: Liang – volume: 19 year: 2005 ident: B11 article-title: T(3;4)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma publication-title: Leukemia doi: 10.1038/sj.leu.2403644 contributor: fullname: Streubel – volume: 11 year: 2019 ident: B2 article-title: Epidemiology of thyroid cancer: A review of the national cancer database, 2000-2013 publication-title: Cureus doi: 10.7759/cureus.4127 contributor: fullname: Olson – volume: 36 year: 2015 ident: B24 article-title: Downregulation of FOXP2 promoter human hepatocellular carcinoma cell invasion publication-title: Tumour Biol doi: 10.1007/s13277-015-3701-y contributor: fullname: Yan – volume: 181 year: 2018 ident: B9 article-title: Members of FOX family could be drug targets of cancers publication-title: Pharmacol Therapeut doi: 10.1016/j.pharmthera.2017.08.003 contributor: fullname: Wang – volume: 10 year: 2009 ident: B8 article-title: The evolution of fox genes and their role in development and disease publication-title: Nat Rev Genet doi: 10.1038/nrg2523 contributor: fullname: Hannenhalli – volume: 11 year: 2020 ident: B30 article-title: Immune cell confrontation in the papillary thyroid carcinoma microenvironment publication-title: Front Endocrinol (Lausanne) doi: 10.3389/fendo.2020.570604 contributor: fullname: Xie – volume: 20 start-page: 4413 year: 2019 ident: B6 article-title: Immune and inflammatory cells in thyroid cancer microenvironment publication-title: Int J Mol Sci doi: 10.3390/ijms20184413 contributor: fullname: Ferrari – volume: 4 start-page: 41 year: 2016 ident: B23 article-title: Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment publication-title: Vaccines-Basel doi: 10.3390/vaccines4040041 contributor: fullname: Poggi – volume: 20 year: 2019 ident: B19 article-title: Knockdown of FOXP1 promotes the development of lung adenocarcinoma publication-title: Cancer Biol Ther doi: 10.1080/15384047.2018.1537999 contributor: fullname: Sheng – volume: 20 year: 2015 ident: B26 article-title: Association of THADA, FOXP4, GPRC6A/RFX6 genes and 8q24 risk alleles with prostate cancer in northern Chinese men publication-title: J BUON contributor: fullname: Li – volume: 8 year: 2015 ident: B28 article-title: MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4) publication-title: Int J Clin Exp Pathol contributor: fullname: Wang – volume: 22 year: 2016 ident: B3 article-title: Thyroid cancer: Risk-stratified management and individualized therapy publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0484 contributor: fullname: Raue – volume: 21 year: 2008 ident: B10 article-title: FOXP1 abnormalities in lymphoma: Translocation breakpoint mapping reveals insights into deregulated transcriptional control publication-title: Modern Pathol doi: 10.1038/modpathol.2008.74 contributor: fullname: Goatly – volume: 19 start-page: 196 year: 2019 ident: B4 article-title: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer publication-title: BMC Cancer doi: 10.1186/s12885-019-5380-3 contributor: fullname: Mehnert – volume: 66 year: 2013 ident: B29 article-title: Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers publication-title: J Clin Pathol doi: 10.1136/jclinpath-2012-201335 contributor: fullname: Stumm – volume: 9 year: 2021 ident: B1 article-title: Thyroid cancer incidence trends by histology in 25 countries: A population-based study publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(21)00027-9 contributor: fullname: Miranda-Filho – volume: 23 start-page: 434 year: 2022 ident: B16 article-title: FOXP2 regulates thyroid cancer cell proliferation and apoptosis via transcriptional activation of RPS6KA6 publication-title: Exp Ther Med doi: 10.3892/etm.2022.11361 contributor: fullname: Yang – volume: 97 year: 2012 ident: B33 article-title: Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer publication-title: J Clin Endocr Metab doi: 10.1210/jc.2011-3428 contributor: fullname: French – volume: 3 year: 2016 ident: B20 article-title: Silencing FOXP2 in breast cancer cells promotes cancer stem cell traits and metastasis publication-title: Mol Cell Oncol doi: 10.1080/23723556.2015.1019022 contributor: fullname: Cuiffo – volume: 11 year: 2019 ident: B15 article-title: Epigenetic control of Foxp3 in intratumoral T-cells regulates growth of hepatocellular carcinoma publication-title: Aging (Albany NY) doi: 10.18632/aging.101918 contributor: fullname: Liu – volume: 10 year: 2014 ident: B21 article-title: FOXP1 has a low expression in human gliomas and its overexpression inhibits proliferation, invasion and migration of human glioma U251 cells publication-title: Mol Med Rep doi: 10.3892/mmr.2014.2197 contributor: fullname: Xue – volume: 143 year: 2016 ident: B7 article-title: Fox transcription factors: From development to disease publication-title: Development doi: 10.1242/dev.112672 contributor: fullname: Golson – volume: 28 year: 2011 ident: B17 article-title: Alternative splicing and gene duplication in the evolution of the FoxP gene subfamily publication-title: Mol Biol Evol doi: 10.1093/molbev/msq182 contributor: fullname: Santos – volume: 50 year: 2017 ident: B27 article-title: Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer publication-title: Cell Proliferat doi: 10.1111/cpr.12312 contributor: fullname: Li – volume: 95 year: 2010 ident: B34 article-title: Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer publication-title: J Clin Endocr Metab doi: 10.1210/jc.2009-2564 contributor: fullname: French – volume: 19 start-page: 3279 year: 2018 ident: B18 article-title: The dominant role of forkhead box proteins in cancer publication-title: Int J Mol Sci doi: 10.3390/ijms19103279. contributor: fullname: Bach – volume: 87 year: 2017 ident: B13 article-title: Circulating thyroid cancer biomarkers: Current limitations and future prospects publication-title: Clin Endocrinol (Oxf) doi: 10.1111/cen.13369 contributor: fullname: Nixon – volume: 29 year: 2019 ident: B31 article-title: Low lymphocyte-to-Monocyte ratios are associated with poor overall survival in anaplastic thyroid carcinoma patients publication-title: Thyroid doi: 10.1089/thy.2018.0684 contributor: fullname: Ahn |
SSID | ssj0000493335 |
Score | 2.3805246 |
Snippet | Background
The clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration... BackgroundThe clinical outcomes are not always favorable in certain thyroid cancer patients. The effect of Forkhead-box family on immune cells infiltration and... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 982812 |
SubjectTerms | clinical prognosis diagnosis FOXP2 immune infiltration Immunology thyroid cancer |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4iCF7EJ64vIngS6rZp0iRHFRcRfBxc2FvIq1jRdlm7B_-9k2ZXticv3kqbknQmzXxfM_0GoQsA5bnl1idWpiyhlmSJAaCc5KXl3koOESoQxcen4n5MHyZsslLqK-SERXngaLhhRjgXThifeUqZ88JoZklRllxaUZSuW30ztkKm3iPuzfOcxW1MYGFyWFafn3Pgg4RcSWAZGekFok6vvwcy-ymSKzFntI22FmARX8dB7qA1X--ijVg-8nsP1VF6GDclHj1PXghuQ-BZLgM4ltLBcBQGVXsMk6n6WMjkhpvAR7OmctgGz8-wrh2u2i88bdqQQgQdL3-bxEES3O-j8eju9fY-WdRPSCylpE2MLmxWCuktMGZOUi1TzYT2RgKsk-FLhs5pbkSWSuK0YY4WFvCYKYjn0lmSH6D1uqn9IcKOcwvNqBbEAIGkmpbOMOq1B0AGIGqALpfGVNMok6GAXgTLq87yKlheRcsP0E0w92_DoHDdnQC_q4Xf1V9-H6DzpbMUvBFhm0PXvpl_KcIBszIBQHOAeM-LvR77V-rqrdPWlrAmkUIc_ccQj9FmeOqQXULSE7Tezub-FCBMa8662foDURHzHA priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYhpdBLaZuUbtsEFXIqOLFlWY9DCUnoEgppe-jC3oRebl0SO_V6ofn3nfEjxJBLb37IljUz0nyfJM8QcgSgPPfSx8TrtEi4Z1niACgneell9FqCh0KiePVVXK74l3Wx3iFTeqtRgJtHqR3mk1q118d__9ydQof_hIwT_O1JWd3cbIHqMXasgUBgzuEnjOccDf5qRPu_BzCc533KzUwInoAp82Gd8_G3zDxVH9B_hkLneygfOKXlC_J8RJP0bFD_S7IT61fk6ZBf8m6P1ENsYtqUdPlt_Z3RDj3TNE7QIdcOhSP8qDpSaH91PcbRxYdAiW1TBerRNFpq60CrbkNvmw73GEHF03-VFGOGx32yWn7-cXGZjAkWEs856xJnhc9KpaMHSi1ZanVqC2Wj04D7NE512JznTmWpZsG6InDhAbA5waLUwbP8Ndmtmzq-ITRI6aEYt4o5YJjc8jK4gkcbAbEBylqQj5Mwze0QR8MA_0DJm17yBiVvBskvyDmK-74ghsDuLzTtTzP2KJMxKVVQLmaR8yJE5WzhmShLqb0SZViQD5OyDHQZXAexdWy2G8MkgNpCARJdEDnT4qzG-Z26-tUH39YwaDGh3v5Pe96RZ3iG20xY-p7sdu02HgCW6dxhb6H_AGiH864 priority: 102 providerName: Scholars Portal |
Title | Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value |
URI | https://search.proquest.com/docview/2723158163 https://pubmed.ncbi.nlm.nih.gov/PMC9531268 https://doaj.org/article/12778d8be1e445de8ba5c26ff79c86fd |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZJIJBLaZuWbJsGFXIqeNfWw5KObegmFLbJoYG9Cb3cumTlZeM99N9n5EeJr7kIY0tInhl7vk8ajRC6BFBOnXAhcyrnGXOkyCwA5YxWTgSnBHioRBRXP8ube_ZjzdcHiI97YbqgfWfreXzYzGP9p4ut3G7cYowTW9ytrhQYDinl4hAdCkqfUfS_PeSllPJ-BRMImFpU9WazBypIyFwBwSjIxAd1qfon-HIaHfnM3Sxfo1cDTsRf-_G8QQchvkXH_cmR_05R7LMO46bCy9v1HcFt8jnjHwD3p-hguEqDigGDHdUPQ4bc1AjUs2tqj11S-g6b6HHdPuJt06boIeh43DGJUzbw8A7dL7__urrJhqMTMscYaTNrSldUUgUHZFmQ3KjccGmCVYDoVJrEMJRRK4tcEW8s96x0AMVsSYJQ3hH6Hh3FJoYzhL0QDqoxI4kF7sgMq7zlLJgAWAzw0wx9GYWpt32GDA3MIkled5LXSfK6l_wMfUvi_l8xJbfubjS733pQsS6IENJLG4rAGPdBWsMdKatKKCfLys_Q51FZGj6GtMJhYmj2j5oIgKtcAsacITHR4qTH6ROwsi6t9mBVH17c8iM6Sa-aoklIfo6O2t0-fALI0tqLjupDeb0uoFwxedEZ7RNrDfOd |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYILb8TyNBInpGQTx47tI1SsFuiWHlq0N8uvQKCbrLbZA_x6xnGCGm5wi2JbjvONM9_E488IvQZSXlhufWJlxhJqSZ4YIMpJUVnureTgoUKguDopl-f045qtDxAb98L0SfvW1GlzsUmb-lufW7nd2PmYJzY_XR1JMBxSivk1dB3mK2FXgvTvkfQWRcHiGiaEYHJe1ZvNHoJBQlIJIUZOJl6oF-ufMMxpfuQVh7O4g76MjxrzTH6k-86k9tdfKo7_PJa76PZAQfHbWHwPHfjmProRD6X8-QA1UdAYtxVefF6fEtwFdzZ-XHA8oAfDVRht4zGYaH0xiO-GRoD8rq0dtsGedlg3DtfdJd62XUhMgo7HzZg4CI37h-h88f7saJkMpzIkllLSJUaXNq-E9BbicE4yLTPNhPZGAlmU4f-ILmhhRJ5J4rRhjpYWWJ4piefSWVI8QodN2_jHCDvOLVSjWhADYSnVtHKGUa890DygZjP0ZkRJbaP4hoKgJUCqekhVgFRFSGfoXcDxT8Wgm93faHdf1fDGVU44F04Yn3tKmfPCaGZJWVVcWlFWboZejVagYJ6FxRPd-HZ_qQgHJswE0NcZ4hPzmPQ4LQHQe8XuAeQn_93yJbq5PFsdq-MPJ5-eolth2CFphWTP0GG32_vnwIw686KfB78BpYMS5A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagCNQL5akuUDASJ6S8HCe2j9CyKo-WPVBpxcXyKxDoJqtt9lB-PeM4QRuOvUWJLceZceb74sk3CL0BUJ4bZlxkRFpE1JAs0gCUo7wyzBnBIEJ5onh2Xp5e0E_LYrlT6qtP2je6jpvLVdzUP_vcyvXKJGOeWLI4OxbgOKTkydpWyW10B9YsYTtE_VcAvnmeF2EfE2iYSKp6tdoCISQkFkAzMjKJRL1g_wRlTnMkd4LO_AB9H2835Jr8jredjs2f_5QcbzSfB-j-AEXxu9DkIbrlmkfobihOef0YNUHYGLcVnn9dLgjufFgbXzI4FOrBcORn3DgMrlpfDiK8vhN4wKatLTberzZYNRbX3RVet51PUIKBx58ysRccd0_QxfzDt-PTaKjOEBlKSRdpVZqs4sIZ4OOMpEqkquDKaQGgUfjvJCqnueZZKohVurC0NID2dEkcE9aQ_Cnaa9rGHSJsGTPQjCpONNBTqmhldUGdcgD3AKLN0NvRUnIdRDgkkBdvVtmbVXqzymDWGXrvbfmvodfP7k-0mx9yeOoyI4xxy7XLHKWFdVyrwpCyqpgwvKzsDL0ePUHCevObKKpx7fZKEgaIuOAAY2eITVxkMuL0Chi-V-4eDP3sxj1foXuLk7n88vH883O072ftc1dI-gLtdZutOwKA1OmX_VL4CyIeFWQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+FOXP2+transcription+factor+on+immune+infiltration+of+thyroid+cancer+and+its+potential+clinical+value&rft.jtitle=Frontiers+in+immunology&rft.au=Xu%2C+Lianghui&rft.au=Yang%2C+Zheyu&rft.au=Zhao%2C+Qiwu&rft.au=Feng%2C+Haoran&rft.date=2022-09-20&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.982812&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_982812 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon |